New international guidelines recommend the use of whole-body imaging in monoclonal plasma cell disorders

New recommendations from the International Myeloma Working Group (IMWG) on the use of imaging methods in monoclonal plasma cell disorders were recently published in The Lancet Oncology. (1) Overall, the guidelines recommend that more sensitive imaging techniques, such as whole-body CT and MRI, be introduced generally into clinical practices for the diagnosis and management of…


NICE to consider lenalidomide maintenance treatment for myeloma patients post high dose therapy and stem cell transplantation

Lenalidomide (Revlimid®) maintenance for myeloma patients who have undergone high dose therapy and stem cell transplantation (HDT-SCT) will be considered for use on the NHS by The National Institute for Health and Care Excellence (NICE) later this year. This announcement comes after updated advice from the manufacturer Celgene and follows publication of data from the Myeloma XI clinical…


P-BCMA-101 Clinical Data Presented at CAR-TCR Summit

Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma Poseida Therapeutics Inc. – a clinical-stage biotechnology company translating best-in-class gene engineering technologies into lifesaving cell therapies – announced data results from the first eleven patients treated in its ongoing Phase 1 study of its…